| Identification | Back Directory | [Name]
Isoquinoline, 1,2-dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]-, (1R)- | [CAS]
952739-54-7 | [Synonyms]
Isoquinoline, 1,2-dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]-, (1R)- | [Molecular Formula]
C24H20N2O2S | [MOL File]
952739-54-7.mol | [Molecular Weight]
400.49 |
| Chemical Properties | Back Directory | [Boiling point ]
651.2±65.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
16.67±0.30(Predicted) | [color ]
white to beige | [InChIKey]
YCOHEPDJLXZVBZ-XMMPIXPASA-N | [SMILES]
O=S(N1[C@@H](C2=CNC3=C2C=CC=C3)C4=CC=CC=C4C=C1)(CC5=CC=CC=C5)=O |
| Hazard Information | Back Directory | [Uses]
(R)-IBR2 is the isomer of IBR2 (HY-103710). IBR2 is a potent and specific RAD51 inhibitor and inhibits RAD51-mediated DNA double-strand break repair. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, inhibits cancer cell growth and induces apoptosis[1]. | [Biological Activity]
IBR2 is a cell penetrantpotent and specific RAD51 inhibitor th at inhibits RAD51-mediated DNA double-strand break repair and enhances cytotoxicity of multiple anticancer agents with disparate biochemical targets including the Bcr-Abl inhibitor imatinib and multiple kinase inhibitor regorafenib. IBR2 disrupts RAD51 multimerizationaccelerates proteasome-mediated RAD51 protein degradationreduces ionizing radiation-induced RAD51 foci formationinhibits cancer cell growth and induces apoptosis. | [References]
[1] Zhu J, et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013 Mar;5(3):353-65. DOI:10.1002/emmm.201201760 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|